Acenta Discovery, Inc.

Basic Information

Acenta Discovery, Inc.
9030 South Rita Road
Tucson, AZ, 85747

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Development of NET-Selective Piperidine-Based PET Ligand

    Amount: $499,986.00

    DESCRIPTION (provided by applicant): World-wide public health surveys point to an increasing global health burden resulting from serious brain disorders, particularly mood-related disorders such as de ...

    STTR Phase I 2005 Department of Health and Human Services
  2. Akt Inhibitors to Treat Ewing's Sarcoma

    Amount: $596,620.00

    DESCRIPTION (provided by applicant): Novel drugs that improve overall survival with decreased morbidity are critical in the war on cancer. Acenta Discovery Inc. has partnered with the Toretsky Lab o ...

    STTR Phase I 2004 Department of Health and Human Services
  3. Caspase Inhibitor for Neuroprotection

    Amount: $348,523.00

    DESCRIPTION (provided by applicant): An important role for apoptosis has been established in various pathological processes, particularly in nervous tissues. Apoptosis essentially contributes to neuro ...

    STTR Phase I 2004 Department of Health and Human Services
  4. NET- Selective Ligands for the Treatment of Depression

    Amount: $545,039.00

    DESCRIPTION (provided by applicant): World-wide public health surveys point to an increased global health burden for serious psychiatric disorders, particularly depression. Indeed, by 2020 it is ex ...

    STTR Phase I 2003 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government